Terminated PHASE1 INTERVENTIONAL 1-arm NCT02720926

Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer

A Phase 1 Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Upfront Treatment of Advanced Colorectal and Gastric Cancer With a Dose Expansion Cohort in Advanced Gastric Cancer

Sponsor: National Cancer Centre, Singapore

Conditions Colorectal Cancer Gastric Cancer

Interventions Oxaliplatin TKI258 Xeloda,

Updated 5 times since 2017 Last updated: Mar 25, 2016 Started: Sep 30, 2011 Primary completion: Jan 31, 2012 Completion: Jan 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Unafavourable toxicity profile

Other terminated trials from National Cancer Centre, Singapore

See all terminations from National Cancer Centre, Singapore

Other Colorectal Cancer trials with similar outcome

Browse all Colorectal Cancer trials

A PHASE1 clinical study on Colorectal Cancer and Gastric Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Centre, Singapore and has accumulated 5 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE1

First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Centre, Singapore
Novartis

Data source: National Cancer Centre, Singapore

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore